Extreme Hypofractionation with SBRT in Localized Prostate Cancer
Authors:
- Maria Antonia Gómez-AparicioMGMaria Antonia Gómez-Aparicio
- Jeannette ValeroJVJeannette Valero
- Begoña CaballeroBCBegoña Caballero
- Rafael GarcíaRGRafael García
- Ovidio Hernando-RequejoOHOvidio Hernando-Requejo
- Ángel MonteroÁMÁngel Montero
- Alfonso Gómez-IturriagaAGAlfonso Gómez-Iturriaga
- Thomas ZilliTZThomas Zilli
- Piet OstPOPiet Ost
- Fernando López-CamposFLFernando López-Campos
- Felipe CouñagoFCFelipe Couñago
Open Access
- 3 August 2021
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 28 (4) , 2933-2949
Abstract
Prostate cancer is the most commonly diagnosed cancer among men around the world. Radiotherapy is a standard of care treatment option for men with localized prostate cancer. Over the years, radiation delivery modalities have contributed to increased precision of treatment, employing radiobiological insights to shorten the overall treatment time, improving the control of the disease without increasing toxicities. Stereotactic body radiation therapy (SBRT) represents an extreme form of hypofractionated radiotherapy in which treatment is usually delivered in 1–5 fractions. This review assesses the main efficacy and toxicity data of SBRT in non-metastatic prostate cancer and discusses the potential to implement this scheme in routine clinical practice.Keywords
This publication has 73 references indexed in Scilit:
- Early Salvage Radiotherapy Following Radical ProstatectomyEuropean Urology, 2014
- Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year studyRadiation Oncology, 2014
- Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trialsRadiotherapy and Oncology, 2013
- Effect of endorectal balloon positioning errors on target deformation and dosimetric quality during prostate SBRTPhysics in Medicine & Biology, 2013
- Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trialThe Lancet, 2011
- External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised studyThe Lancet Oncology, 2010
- Prostate Cancer–Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical ProstatectomyJAMA, 2008
- Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial resultsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- The radiobiology of prostate cancer including new aspects of fractionated radiotherapyActa Oncologica, 2005
- Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005